Empirical therapy advisor

Before culture results are back: how likely is each antibiotic to cover the pathogen of a patient like this one, in this ward, given the last 12 months of results and today's alerts.

Patient

More options · any onset · target 80 % · 2025-08-10
Based on 1118 first isolates · ED · Cystitis (lower UTI) · 2024-08-11 → 2025-08-10
Emergency department
Per-organism detail: ED urine resistance view →
Narrowest option reaching 80 % coverage, no active warning
nitrofurantoin 85 % (83 %–87 %)
No tissue or blood levels: cystitis only.
Not covered: Proteus mirabilis (6 %), Pseudomonas aeruginosa (5 %), Klebsiella pneumoniae (3 %)
AntibioticCoverage, 12 months (95 % CI)12 mo4 wk
nitrofurantoin NIT
trend · Escherichia coli lower UTI only
85 %
83 %
n = 92
meropenem MEM
trend · Escherichia coli reserve
85 %
85 %
n = 92
piperacillin-tazobactam TZP
trend · Escherichia coli broad spectrum
81 %
79 %
n = 92
ciprofloxacin CIP
trend · Escherichia coli
79 %
82 %
n = 92
mecillinam MEC
trend · Escherichia coli lower UTI only
78 %
77 %
n = 92
ceftriaxone CRO
trend · Escherichia coli
76 %
79 %
n = 92
trimethoprim TMP
trend · Escherichia coli lower UTI only
74 %
70 %
n = 92
73 %
74 %
n = 92
53 %
50 %
n = 92
vancomycin VAN
trend · Enterococcus faecalis Gram-positive only
13 %
14 %
n = 92
5 %
4 %
n = 92
clindamycin CLI
trend · Staphylococcus aureus Gram-positive only
3 %
1 %
n = 92

Most likely organisms for this profile

Escherichia coli
56 %
Klebsiella pneumoniae
11 %
Enterococcus faecalis
10 %
Proteus mirabilis
6 %
Pseudomonas aeruginosa
5 %
Klebsiella oxytoca
4 %

Decision support only: coverage is the share of first isolates from similar patients that were susceptible (an organism not tested for a drug counts as not covered). It does not replace local treatment guidelines, allergy and severity assessment, or clinical judgement. The black tick on each bar is the coverage target; the bracket is the 95 % confidence interval.

AEI · Tyks Laboratoriot × Mylab · JunctionX Turku. Synteettinen aineisto; EARS-Net-luvut: ECDC.